Authorization

Verona Pharma to Present at H.C. Wainwright Global Life Sciences Virtual Conference

LONDON and RALEIGH, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (a??Verona Pharmaa??), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the H.C. Wainwright Global Life Sciences Conference. The presentation will be available on-demand starting at 7:00 AM ET on Tuesday, March 9, 2021.
A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Companya??s website,A www.veronapharma.com.









Verona Pharma plc



US Tel: +1-833-417-0262
UK Tel: +44 (0)20 3283 4200



Victoria Stewart, Director of Communications



info@veronapharma.com











Argot Partners
(US Investor Enquiries)



Tel: +1-212-600-1902
verona@argotpartners.com



Kimberly Minarovich / Michael Barron















Optimum Strategic Communications
(International Media and European Investor Enquiries)



Tel: +44 (0)203 950 9144
verona@optimumcomms.com



Mary Clark / Eva Haas / Shabnam Bashir





About Verona PharmaVerona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharmaa??s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (a??Ensifentrine as a Novel inHAled Nebulized COPD thErapya??) for COPD maintenance treatment. Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (a??DPIa??) and pressurized metered-dose inhaler (a??pMDIa??). Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visitA www.veronapharma.com.Forward-Looking Statements
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Апрель 2021    »
ПнВтСрЧтПтСбВс
 1234
567891011
12131415161718
19202122232425
2627282930